CL2007003276A1 - Metodo para administrar una cantidad eficaz de un agente activo de bisfosfonatos, mediante una via pulmonar; composicion farmaceutica que comprende a dichos bisfosfonatos; y kit farmaceutico que comprende a dichos bisfosfonatos. - Google Patents

Metodo para administrar una cantidad eficaz de un agente activo de bisfosfonatos, mediante una via pulmonar; composicion farmaceutica que comprende a dichos bisfosfonatos; y kit farmaceutico que comprende a dichos bisfosfonatos.

Info

Publication number
CL2007003276A1
CL2007003276A1 CL200703276A CL2007003276A CL2007003276A1 CL 2007003276 A1 CL2007003276 A1 CL 2007003276A1 CL 200703276 A CL200703276 A CL 200703276A CL 2007003276 A CL2007003276 A CL 2007003276A CL 2007003276 A1 CL2007003276 A1 CL 2007003276A1
Authority
CL
Chile
Prior art keywords
bisphosphonates
managing
effective amount
pharmaceutical composition
pulmonary route
Prior art date
Application number
CL200703276A
Other languages
English (en)
Inventor
Toru Yamamoto Akira Nakat Hibi
Original Assignee
Teikoku Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc filed Critical Teikoku Pharma Usa Inc
Publication of CL2007003276A1 publication Critical patent/CL2007003276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200703276A 2006-11-21 2007-11-14 Metodo para administrar una cantidad eficaz de un agente activo de bisfosfonatos, mediante una via pulmonar; composicion farmaceutica que comprende a dichos bisfosfonatos; y kit farmaceutico que comprende a dichos bisfosfonatos. CL2007003276A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86678706P 2006-11-21 2006-11-21
PCT/US2007/083742 WO2008063865A2 (en) 2006-11-21 2007-11-06 Biphosphonate inhalant formulations and methods for using the same
US11/935,764 US20080132471A1 (en) 2006-11-21 2007-11-06 Bisphosphonate inhalant formulations and methods for using the same

Publications (1)

Publication Number Publication Date
CL2007003276A1 true CL2007003276A1 (es) 2008-05-30

Family

ID=39430445

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703276A CL2007003276A1 (es) 2006-11-21 2007-11-14 Metodo para administrar una cantidad eficaz de un agente activo de bisfosfonatos, mediante una via pulmonar; composicion farmaceutica que comprende a dichos bisfosfonatos; y kit farmaceutico que comprende a dichos bisfosfonatos.

Country Status (16)

Country Link
US (1) US20080132471A1 (es)
EP (1) EP2086330A4 (es)
JP (1) JP2010510230A (es)
KR (1) KR20090083326A (es)
CN (1) CN101522032A (es)
AR (1) AR064269A1 (es)
AU (1) AU2007324044A1 (es)
BR (1) BRPI0714776A2 (es)
CA (1) CA2658834A1 (es)
CL (1) CL2007003276A1 (es)
EA (1) EA200900095A1 (es)
IL (1) IL196644A0 (es)
MX (1) MX2009001271A (es)
TW (1) TW200835504A (es)
WO (1) WO2008063865A2 (es)
ZA (1) ZA200900603B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076480A2 (en) 2007-12-10 2009-06-18 Synthetic Genomics, Inc. Methylbutanol as an advanced biofuel
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
KR20110079813A (ko) * 2008-09-22 2011-07-08 아이시스 이노베이션 리미티드 이미다조〔1,2－α〕피리디닐 비스포스포네이트
CN105640924B (zh) * 2016-01-18 2018-11-02 杭州旦杰医学科技有限公司 用于呼吸道给药的阿仑膦酸钠粉雾剂及其制备方法和用途
CN107441101A (zh) * 2017-09-04 2017-12-08 杭州旦承医药科技有限公司 伊班膦酸钠的用途及粉雾剂和制备方法
CN107550919A (zh) * 2017-09-04 2018-01-09 杭州旦承医药科技有限公司 唑来膦酸的用途及粉雾剂和制备方法
CN107375306A (zh) * 2017-09-04 2017-11-24 杭州旦承医药科技有限公司 利塞膦酸钠的用途及粉雾剂和制备方法
CN111053761B (zh) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
ATE176476T1 (de) * 1992-12-02 1999-02-15 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6414006B1 (en) * 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
US20050008633A1 (en) * 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions

Also Published As

Publication number Publication date
EA200900095A1 (ru) 2009-08-28
JP2010510230A (ja) 2010-04-02
WO2008063865A2 (en) 2008-05-29
WO2008063865A3 (en) 2008-10-16
MX2009001271A (es) 2009-02-11
CN101522032A (zh) 2009-09-02
IL196644A0 (en) 2009-11-18
TW200835504A (en) 2008-09-01
EP2086330A2 (en) 2009-08-12
AR064269A1 (es) 2009-03-25
EP2086330A4 (en) 2010-10-20
KR20090083326A (ko) 2009-08-03
AU2007324044A1 (en) 2008-05-29
US20080132471A1 (en) 2008-06-05
BRPI0714776A2 (pt) 2013-07-16
CA2658834A1 (en) 2008-05-29
ZA200900603B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
CL2007003276A1 (es) Metodo para administrar una cantidad eficaz de un agente activo de bisfosfonatos, mediante una via pulmonar; composicion farmaceutica que comprende a dichos bisfosfonatos; y kit farmaceutico que comprende a dichos bisfosfonatos.
CR20110110A (es) Composicion farmaceutica
FR21C1025I2 (fr) Composition parasiticide comprenant un agent actif d'isoxazoline, son procede et utilisation
DK3103448T3 (da) Farmaceutiske sammensætninger, der omfatter en S1P-modulator
BRPI0815766A2 (pt) Composição pesticida, e, método para potencializar a eficácia de um ingrediente ativo pesticida.
BRPI0913587A2 (pt) Composição, agente pesticida, método para controlar fundos prejudiciais fitopatogênicos, semente, uso de um composto e de um outro composto, e, composição.
WO2012027065A3 (en) Combination therapy for treatment of disease
IL193274A0 (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
CL2007003743A1 (es) Composicion que comprende fenamidona y un compuesto insecticida; y metodo para controlar de forma curativa o preventiva hongos fitopatogenos de cultivos e insectos.
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
DK2125789T3 (da) Pyrimidinylpyrazoler som insekticide og parasiticide aktivstoffer
DK2058317T3 (da) Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens
BRPI0910759A2 (pt) sistema e método para dispensar um agente de benefício hidrofóbicos a um substrato queratinoso, e, composição de enxágue corporal
NO20075111L (no) Farmasoytisk sammensetning
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BRPI0912068A2 (pt) "uso em armazenamento de uma tubulação, método, uso em enrolamento sobre uma bobina de uma tubulação, uso na distribuição de uma tubulação, sistema, para uso no realinhamento de uma tubulação, para uso na entrega de uma tubulação de um primeiro lecal"
BRPI0911856A2 (pt) técnica híbrida de cirurgia endoscópica-laparoscópica para a inserção de efetores de extremidade através de um orifício natural.
CL2008000217A1 (es) Combinaciones de compuestos activos que comprenden la formononetina y al menos un compuesto activo; uso de dicha combinacion para controlar hongos fitopatogenos no deseados; y procedimiento para controlar hongos fitopatogenos no deseados.
BRPI0905707A2 (pt) Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
FR2938192B1 (fr) Nouvel actif anti-vergetures et compositions le comprenant
CL2014002414A1 (es) Composicion farmaceutica inyectable que comprende ibuprofeno, una solucion acuosa y un agente solubilizante seleccionado de fosfatos de sodio, de potasio, carbonatos de sodio, de potasio y/o combinaciones de ellos.
CL2007003717A1 (es) Composicion insecticida para semillas o cultivos cosechados; metodo para prevenir danos hechos por un insecto; y metodos para preservar semillas y cultivos cosechados.
NI200900112A (es) Agentes para combatir parásitos en animales.
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina